Shionogi Takes Full Control of Sleep Science Venture, Signaling Consolidation in Sleep Disorder Treatment
OSAKA, Japan – In a strategic move signaling a deepening commitment to sleep disorder therapies, Shionogi & Co., Ltd. Announced on March 23, 2026, that it will acquire Apnimed, Inc.’s equity interest in their joint venture, Shionogi-Apnimed Sleep Science, LLC (SASS). This acquisition, valued at USD 100 million, will result in SASS becoming a wholly-owned subsidiary of Shionogi, effective April 6, 2026.
The Evolution of a Partnership
Established in 2023, SASS was formed to address the significant unmet needs in the field of sleep disorders. The joint venture combined Shionogi’s expertise in small-molecule drug discovery with Apnimed’s translational research capabilities. This collaboration has yielded promising development programs, including SASS-001 and SASS-002 (sulthiame), alongside several new drug discovery projects.
Why the Full Acquisition?
According to Shionogi, the decision to fully acquire SASS stems from a desire to accelerate the delivery of new treatment options for patients. After extensive discussions, Shionogi determined that complete ownership would allow for more efficient advancement of the pipeline. This move underscores the growing importance of the sleep disorder market and Shionogi’s ambition to become a leading player.
Key Assets Under Shionogi’s Wing
The acquisition grants Shionogi full control over the research, development and commercialization of SASS’s key assets, including:
- SASS-001: A novel oral drug for sleep apnea with a central component, combining sivopixant with another active compound. Currently in a Phase 2a clinical trial (RESTEADY study).
- SASS-002 (sulthiame): A carbonic anhydrase inhibitor showing favorable results in a Phase 2 trial for obstructive sleep apnea (OSA).
- Ongoing Drug Discovery Programs: A portfolio of early-stage projects aimed at addressing various sleep disorders.
The Expanding Market for Sleep Disorder Treatments
The global sleep disorder market is experiencing substantial growth, driven by increasing awareness, diagnosis rates, and a growing aging population. OSA, in particular, affects millions worldwide, with an estimated 80 million individuals in the United States alone. Current treatment options, such as CPAP machines, are often poorly tolerated, creating a significant demand for alternative therapies.
Sulthiame: A Potential Game-Changer for OSA?
SASS-002, sulthiame, has demonstrated promising results in Phase 2 trials, offering a potential oral medication for OSA patients. The drug’s mechanism of action as a carbonic anhydrase inhibitor provides a novel approach to treating the condition. If successful in later-stage trials, sulthiame could represent a significant advancement in OSA treatment, offering a more convenient and tolerable option for patients.
Shionogi’s Strategic Focus
This acquisition aligns with Shionogi’s broader strategy to focus on areas with significant unmet medical needs. The company is actively investing in research and development in pain/CNS disorders, oncology, rare diseases, and now, sleep apnea. Shionogi anticipates that its strengthened position in sleep disorders will contribute to mid- to long-term growth.
FAQ
Q: What is SASS?
A: Shionogi-Apnimed Sleep Science, LLC was a joint venture between Shionogi and Apnimed focused on developing treatments for sleep disorders.
Q: What is the acquisition price?
A: Shionogi will acquire Apnimed’s equity interest in SASS for USD 100 million (JPY 15,952 million).
Q: What are SASS-001 and SASS-002?
A: SASS-001 is a drug candidate for central sleep apnea, and SASS-002 (sulthiame) is a drug candidate for obstructive sleep apnea.
Q: When will SASS become a wholly-owned subsidiary of Shionogi?
A: The acquisition is expected to be completed on April 6, 2026.
Did you understand? The prevalence of sleep apnea is often underestimated, with many cases going undiagnosed. Early diagnosis and treatment are crucial for preventing serious health complications.
Pro Tip: If you experience symptoms of sleep apnea, such as loud snoring, daytime sleepiness, or morning headaches, consult with a healthcare professional for evaluation and potential treatment options.
For Further Information:
